Th22和Th17细胞在宫颈癌患者外周血中的表达

Abstract
Figure/Table
References (0)
Related Citation (12)

Download: PDF (1343 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression of Th22 and Th17 cells in the peripheral blood of patients with cervical cancer as well as its association with clinical pathologic features of cervical cancer patients.Methods: Flow cytometry was used to assess the frequency of Th22 and Th17 cells in the peripheral blood of chronic cervicitis (CCS), cervical intraepithelialneoplasia (CIN) and cervical cancer (CC) patients. ELISA method was performed to detect the levels of IL-22, IL-17 and TNF-α in serum. Results: The expression of Th22 and Th17 cells were both elevated in CC and CIN patients in comparison with CCS patients. In CC patients, high Th22 expression was closely correlated with higher incidence of lymph node status. In comparison with the CCS group, levels of IL-22, IL-17 and TNF-α were significantly increased in CC and CIN patient. Conclusion: Our results demonstrate that there is a higher circulatory frequency of Th22 and Th17 in CC, and changes of Th22 cells, Th17 cells and related cytokines may conjointly participate in the pathogenesis and growth of CC.

Key words： Th22 Th17 cervical cancer IL-22

Received: 14 May 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Yunshuang
	ZHOU Wangzhan
	ZHANG Ying
	HE Wei.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I3/210

[1] PRYOR R J, MASROOR N, STEVENS M, et al. Cervical cancer screening in rural mountainous Honduras: knowledge, attitudes and barriers[J]. Rural Remote Health, 2017, 17(2): 3820.
[2] JIN Y, QIU S, SHAO N, et al. Association of toll-like receptor gene polymorphisms and its interaction with HPV infection in determining the susceptibility of cervical cancer in Chinese Han population[J]. Mamm Genome, 2017, 28(5-6): 213-219.
[3] HOU F, LI Z, MA D, et al. Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes inpatients with uterine cervical cancer[J]. Clin Chim Acta, 2012, 413(23-24): 1848-1854.
[4] DUHEN T, GEIGER R, JARROSSAY D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells[J]. Nat Immunol, 2009, 10(8): 857-863.
[5] GIBSON S A, YANG W, YAN Z, et al. Protein kinase CK2 controls the fate between Th17 cell and regulatory T cell differentiation[J]. J Immunol, 2017, 198(11): 4244-4254.
[6] PUNT S, FLEUREN G J, KRITIKOU E, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer[J]. Oncoimmunology, 2015, 4(1): e984539.
[7] WILCZYNSKI S P, BERGEN S, WALKER J, et al. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types[J]. Hum Pathol, 1988, 19(6): 697-704.
[8] BOSCH F X, MANOS M M, MUNOZ N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group[J]. J Natl Cancer Inst, 1995, 87(11): 796-802.
[9] MAHAIRIDOU A, RODOPOULOU S, TOMOS I, et al. Exhaled breath condensate acidification occurs during surgery for abdominal cancer[J]. Anticancer Res, 2017, 37(6): 3315-3321.
[10] LEVILLAYER F, MAS M, LEVI-ACOBAS F, et al. Interleukin 22 is a candidate gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases[J]. Genetics, 2007, 176(3): 1835-1844.
[11] ZENEWICZ L A, FIAVELL R A. Recent advances in IL-22 biology[J]. Int Immunol, 2011, 23(3): 159-163.
[12] SONNENBERG G F, FOUSER L A, ARTIS D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces[J]. Adv Immunol, 2010, 107: 1-29.
[13] ZHANG W, TIAN X, MUMTAHANA F, et al. The existence of Th22, pure Th17 and Th1 cells in CIN and cervical cancer along with their frequency variation in different stages of cervical cancer[J]. BMC Cancer, 2015, 15: 717.